ArticleFrontiers in medicine2023
The efficacy of botulinum toxin type A treatment and surgery for acute acquired comitant esotropia.
Article in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- Comparative efficacy of botulinum toxin and surgical treatment for acute acquired concomitant esotropia: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- A bibliometric analysis of strabismus (from 2004 to 2023).Frontiers in medicine · 2025Pooled it
- Risk factors and predictors for botulinum toxin type A reinjection within six months in patients with acute acquired concomitant esotropia.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Clinical efficacy, safety, and success factors of botulinum toxin type A in the treatment of acute acquired comitant esotropia.Japanese journal of ophthalmology · 2026Article
- Binasal occlusion for the non-invasive management of acute acquired comitant esotropia.Frontiers in medicine · 2026Article
- The COVID-19 pandemic and the abrupt changes in the reported cases of acute acquired comitant esotropia.BMC ophthalmology · 2025Article
- Botulinum toxin for acute acquired comitant esotropia: clinical outcomes and predictors.BMC ophthalmology · 2025Article
- Efficacy of botulinum toxin and surgery in managing acute acquired comitant esotropia.Eye and vision (London, England) · 2025Article
- Botulinum toxin-A in acute acquired comitant esotropia during COVID pandemic in children and young adolescents.Indian journal of ophthalmology · 2025Article
- Advances in the diagnosis and treatment of acute acquired comitant esotropia.International ophthalmology · 2024Review
- Botulinum toxin type A in treating early-stage patients with small-angle acute acquired comitant esotropia.International journal of ophthalmology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To compare the long-term efficiency of botulinum toxin type A (BTXA) injection and surgery on acute acquired comitant esotropia (AACE). Methods: This retrospective study enrolled patients with AACE from January 2020 to August 2022. The horizontal angle of deviation pre- and post-treatment was measured. Deviations in BTXA and surgical treatment were compared. The BTXA group was divided into adequate treatment (AT) and inadequate treatment (inAT) subgroup based on the deviation of no more than 4 prism diopters (at near and distance) or temporary exotropia at the 2 week follow-up. The two subgroups were compared to determine the long-term efficacy of BTXA treatment. Results: Ninety-two patients with AACE were included. Follow-up was 6 months. The deviations of the surgery and BTXA group were significantly smaller at the 6 month follow-up than at pre-treatment ( Conclusion: Surgery and BTXA successfully treat AACE. Surgery has a more precise and lasting therapeutic effect than BTXA. AACE patients adequately treated with BTXA and with deviations of no more than 4 prism diopters at 2 weeks follow-up had better outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.